Compare OOMA & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OOMA | JSPR |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 565.7M | 26.3M |
| IPO Year | 2015 | 2019 |
| Metric | OOMA | JSPR |
|---|---|---|
| Price | $21.11 | $0.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $18.77 | $15.50 |
| AVG Volume (30 Days) | ★ 428.3K | 335.0K |
| Earning Date | 05-27-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 188.46 | 19.22 |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $114,490,000.00 | N/A |
| Revenue This Year | $20.35 | N/A |
| Revenue Next Year | $4.17 | N/A |
| P/E Ratio | $105.90 | ★ N/A |
| Revenue Growth | ★ 9.53 | N/A |
| 52 Week Low | $9.79 | $0.32 |
| 52 Week High | $26.19 | $2.69 |
| Indicator | OOMA | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 41.01 | 51.23 |
| Support Level | $19.66 | $0.64 |
| Resistance Level | $21.57 | $0.67 |
| Average True Range (ATR) | 0.80 | 0.06 |
| MACD | -0.24 | 0.00 |
| Stochastic Oscillator | 8.03 | 61.82 |
Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that delivers voice and collaboration features, including messaging, intelligent virtual attendants, and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.